Double maintains 1 strategies that include AZN - AstraZeneca PLC
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBIL | 0.38% | $784.60M | 0.15% |
| GBIL | -0.39% | $6.36B | 0.12% |
| PDBC | 0.48% | $4.52B | 0.59% |
| BIL | -0.55% | $41.93B | 0.1356% |
| TFLO | -0.57% | $6.74B | 0.15% |
| DBC | -0.78% | $1.27B | 0.87% |
| XHLF | 0.84% | $1.73B | 0.03% |
| AGZD | 0.86% | $98.56M | 0.23% |
| EZBC | 0.98% | $570.81M | 0.29% |
| IVOL | 0.98% | $342.69M | 1.02% |
| FBTC | 1.05% | $22.25B | 0.25% |
| BITO | 1.06% | $2.61B | 0.95% |
| BRRR | 1.06% | $641.19M | 0.25% |
| ARKB | 1.08% | $5.25B | 0.21% |
| YBTC | 1.09% | $226.57M | 0.96% |
| BTCW | 1.10% | $168.52M | 0.3% |
| GBTC | 1.12% | $20.03B | 1.5% |
| COMT | 1.14% | $617.76M | 0.48% |
| BITB | 1.15% | $4.36B | 0.2% |
| BTCO | 1.20% | $574.02M | 0.39% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PPH | 69.77% | $584.35M | 0.36% |
| IXJ | 64.12% | $3.75B | 0.41% |
| EWL | 59.50% | $1.33B | 0.5% |
| EWU | 56.31% | $3.02B | 0.5% |
| IHE | 55.78% | $551.02M | 0.39% |
| FLGB | 55.01% | $786.15M | 0.09% |
| IYH | 54.71% | $2.72B | 0.39% |
| XLV | 54.34% | $34.17B | 0.09% |
| VHT | 53.78% | $15.34B | 0.09% |
| IDHQ | 53.35% | $463.91M | 0.29% |
| FHLC | 53.05% | $2.43B | 0.084% |
| FICS | 53.02% | $223.13M | 0.7% |
| EFAV | 52.54% | $5.46B | 0.2% |
| QEFA | 51.69% | $909.99M | 0.3% |
| HDEF | 51.62% | $2.03B | 0.09% |
| IEV | 51.51% | $2.30B | 0.61% |
| BBEU | 51.40% | $4.59B | 0.09% |
| ACWV | 51.05% | $3.33B | 0.2% |
| SPEU | 51.03% | $693.33M | 0.07% |
| KXI | 50.83% | $853.43M | 0.41% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -27.92% | $184.73M | 0.85% |
| TAIL | -27.59% | $94.86M | 0.59% |
| CLIP | -18.61% | $1.55B | 0.07% |
| USDU | -17.30% | $129.80M | 0.5% |
| UUP | -15.75% | $196.45M | 0.77% |
| TPMN | -12.58% | $31.06M | 0.65% |
| FTSD | -9.80% | $233.11M | 0.25% |
| CANE | -9.60% | $11.14M | 0.29% |
| UGA | -8.14% | $76.33M | 0.97% |
| TBLL | -6.34% | $2.12B | 0.08% |
| KCCA | -5.64% | $108.37M | 0.87% |
| DBE | -5.57% | $54.61M | 0.77% |
| SGOV | -5.46% | $50.93B | 0.09% |
| BNO | -4.45% | $110.71M | 1% |
| USO | -4.18% | $1.06B | 0.6% |
| USL | -3.61% | $43.93M | 0.85% |
| BTAL | -2.97% | $315.93M | 1.43% |
| OILK | -2.91% | $74.12M | 0.69% |
| BILZ | -2.49% | $851.85M | 0.14% |
| WEAT | -2.20% | $123.28M | 0.28% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PRA | -0.05% | $1.22B | +106.78% | 0.00% |
| SBSI | -0.06% | $940.56M | +9.69% | 4.66% |
| DSP | 0.07% | $853.41M | +32.56% | 0.00% |
| GME | -0.11% | $10.33B | -9.66% | 0.00% |
| NGVC | 0.12% | $896.90M | +65.59% | 1.17% |
| STRA | -0.14% | $1.96B | -26.84% | 2.98% |
| COCO | -0.16% | $2.11B | +22.26% | 0.00% |
| CLS | -0.20% | $18.26B | +167.03% | 0.00% |
| UEIC | 0.22% | $92.06M | -42.89% | 0.00% |
| GIII | 0.23% | $1.03B | -11.48% | 0.00% |
| CNDT | -0.24% | $443.41M | -21.49% | 0.00% |
| PRIM | 0.25% | $4.59B | +64.04% | 0.35% |
| CNK | -0.25% | $3.43B | +38.45% | 0.53% |
| CSTE | 0.26% | $62.89M | -66.36% | 0.00% |
| ORN | -0.28% | $342.14M | -1.37% | 0.00% |
| PGNY | 0.31% | $2.02B | -16.22% | 0.00% |
| WTI | 0.34% | $262.82M | -24.58% | 2.26% |
| PACB | -0.37% | $450.13M | 0.00% | 0.00% |
| CHCO | 0.41% | $1.82B | +13.99% | 2.46% |
| RLGT | -0.41% | $292.76M | +8.00% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DFDV | -15.13% | $363.21M | +2,422.23% | 0.00% |
| TDUP | -11.96% | $807.63M | +285.88% | 0.00% |
| LIND | -10.51% | $730.35M | +34.17% | 0.00% |
| ARIS | -10.45% | $749.12M | +42.11% | 2.11% |
| VMEO | -10.01% | $663.92M | +6.61% | 0.00% |
| CYCN | -7.83% | $11.40M | +5.03% | 0.00% |
| CNTY | -7.67% | $73.33M | -3.63% | 0.00% |
| ACIC | -7.61% | $525.12M | +7.01% | 0.00% |
| GALT | -7.60% | $155.06M | +3.81% | 0.00% |
| UUU | -7.07% | $8.22M | +134.65% | 0.00% |
| ALAB | -6.76% | $16.00B | +75.95% | 0.00% |
| CCRN | -6.63% | $408.48M | -8.25% | 0.00% |
| LTM | -6.28% | $12.85B | -95.43% | 2.39% |
| QUAD | -6.24% | $292.03M | -1.54% | 4.41% |
| WTTR | -6.00% | $1.01B | -7.77% | 2.83% |
| SIBN | -5.90% | $800.30M | +27.49% | 0.00% |
| HUSA | -5.89% | $20.99M | -8.33% | 0.00% |
| EE | -5.83% | $873.19M | +41.84% | 0.75% |
| PINC | -5.73% | $1.77B | +13.85% | 3.92% |
| AGL | -5.73% | $956.23M | -62.44% | 0.00% |
Current Value
$70.991 Year Return
Current Value
$70.991 Year Return
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NVS | 62.97% | $234.79B | +11.97% | 3.25% |
| GSK | 60.04% | $80.01B | +1.75% | 4.17% |
| GMAB | 48.96% | $13.45B | -16.69% | 0.00% |
| LIN | 47.53% | $221.40B | +8.15% | 1.24% |
| PFE | 46.75% | $146.57B | -10.05% | 6.62% |
| SNY | 46.61% | $120.21B | -3.65% | 4.51% |
| TAK | 46.28% | $46.71B | +10.75% | 4.49% |
| LLY | 45.02% | $749.33B | -15.36% | 0.71% |
| ECL | 43.74% | $75.64B | +9.12% | 0.95% |
| MRK | 43.69% | $210.98B | -34.85% | 3.82% |
| HLN | 42.35% | $45.41B | +14.89% | 1.77% |
| YUM | 40.79% | $42.35B | +17.63% | 1.82% |
| UL | 40.38% | $150.82B | +8.55% | 3.19% |
| IFF | 40.18% | $19.60B | -21.47% | 2.11% |
| BIIB | 40.17% | $19.83B | -42.85% | 0.00% |
| IQV | 40.06% | $28.64B | -24.57% | 0.00% |
| DTE | 39.83% | $27.74B | +18.10% | 3.23% |
| SBAC | 39.63% | $25.01B | +10.93% | 1.80% |
| XWDIX | 39.50% | - | - | 11.98% |
| TMO | 39.28% | $162.60B | -20.63% | 0.38% |
Yahoo
Functional dyspepsia, marked by untraceable upper abdominal discomfort, is seeing innovation through pharmacological treatments, lifestyle changes, and alternative therapies like herbal and microbiome modulation. Investment in digital health and GI research is boosting symptom management, while refined diagnostic criteria aid identification. Challenges such as symptom overlap and treatment limitations persist, yet AI-driven patient solutions are promising. North America leads the market due to a
SeekingAlpha
ClearBridge Global Value Improvers Strategy Q2 2025 Commentary
Yahoo
The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.
Yahoo
Anal cancer is a rare yet increasing cancer linked primarily to high-risk HPV strains such as HPV-16 and HPV-18. Key risk factors include weakened immune systems, age over 50, and high-risk sexual behaviors. Symptoms encompass rectal bleeding, pain, and changes in bowel habits. Early detection through HPV vaccination and screenings is vital, yet challenges persist due to limited early detection protocols. The market is expanding, driven by rising HPV cases and advancements in immunotherapy and c
Yahoo
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Going Wild. Summit Therapeutics jumped by 7.61 percent on Wednesday, a second day, to close at $24.74 apiece as reports about a $15-billion partnership with AstraZeneca continued to excite investors. In a report by Bloomberg last week, Summit Therapeutics Inc. (NASDAQ:SMMT) was reportedly in talks with AstraZeneca […]
Yahoo
PALM BEACH GARDENS, Fla., July 10, 2025--Eolas Therapeutics today announced that it has entered into a new agreement with AstraZeneca to assume full development rights to AZD4041, an investigational therapy targeting the orexin-1 receptor, for the treatment of opioid use disorder (OUD) and other substance use disorders. Terms of the agreement are confidential.
